What is the total amount of debt Elevance Health raised in this offering?

Elevance Health raised approximately $1.78 billion in net proceeds from the sale of its notes after deducting underwriting discounts and offering expenses.

How will Elevance Health use the proceeds from this notes offering?

The company intends to use the net proceeds for working capital and general corporate purposes, which may include funding acquisitions, repaying debt (both short-term and long-term), and repurchasing its common stock.

What are the key terms and maturity dates of the new notes?

The offering included $400.0 million of 5.350% Notes due October 15, 2025, $650.0 million of 5.500% Notes due October 15, 2032, and $750.0 million of 6.100% Notes due October 15, 2052.

Under what conditions can Elevance Health redeem these notes before maturity?

Elevance Health can redeem the notes at its option under certain conditions. Prior to specified "Par Call Dates" (which are a few months before maturity), redemption involves a calculation based on present values plus a spread. On or after the Par Call Dates, redemption is at 100% of the principal amount plus accrued interest.

What happens if there is a change of control at Elevance Health?

If a change of control event occurs and, within a specified period, a series of notes is downgraded below investment grade by Moody's, S&P, and Fitch, Elevance Health will be required to make an offer to purchase all of the affected notes at 101% of their principal amount, plus accrued and unpaid interest.

ELV 8-K SEC Disclosure

Summary

Elevance Health, Inc. (ELV) announced the closing of a notes offering on November 4, 2022, raising a total of approximately $1.78 billion after deducting underwriting discounts and expenses. This offering consisted of three tranches: $400.0 million in 5.350% Notes due 2025, $650.0 million in 5.500% Notes due 2032, and $750.0 million in 6.100% Notes due 2052. The net proceeds from this issuance are earmarked for general corporate purposes, including working capital, potential acquisitions, debt repayment, and share repurchases. This debt issuance provides Elevance Health with significant financial flexibility to pursue strategic initiatives and manage its capital structure. The terms of the notes include specific redemption provisions, both at the company's option and under certain "change of control" scenarios coupled with a credit rating downgrade. Investors should note the differing interest rates and maturity dates across the three series of notes, reflecting varying terms and market conditions at the time of issuance.

Key Highlights

1Elevance Health closed a debt offering totaling approximately $1.78 billion on November 4, 2022.
2The offering comprised three series of notes: $400M (5.350% due 2025), $650M (5.500% due 2032), and $750M (6.100% due 2052).
3Net proceeds will be used for general corporate purposes, including working capital, acquisitions, debt repayment, and share repurchases.
4The Indenture governing the notes does not restrict the company or its subsidiaries from incurring additional indebtedness.
5Notes are redeemable at the company's option, with call protection periods that vary by series.
6A change of control event, combined with a credit rating downgrade, triggers an offer to repurchase notes at 101% of principal plus accrued interest.

Elevance Health, Inc. 8-K Report, Corporate Update (Nov 4, 2022)

Summary

Key Highlights

Frequently Asked Questions